DiaMedica Therapeutics (DMAC)
Develops DM199 for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Something off on this page? Send us feedback.
Develops the investigational recombinant tissue kallikrein-1 candidate DM199 for preeclampsia, fetal growth restriction, and acute ischemic stroke. The clinical-stage company depends on clinical testing, regulatory actions, trial collaborators, and continued funding.
Develops DM199 (rinvecalinase alfa), an investigational recombinant form of tissue kallikrein-1, for preeclampsia and fetal growth restriction alongside acute ischemic stroke. The program is the clinical lead, and its safety and effectiveness have not been established. Both programs remain in clinical development at present.
In maternal vascular disease, clinical work includes a study at Tygerberg Hospital in Cape Town and preparation for an early-onset-preeclampsia study in North America and the UK. ReMEDy2 is the resumed acute-ischemic-stroke program. Progress depends on clinical testing, regulatory actions, third-party trial collaborators, and continued funding.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $43.5M · Total debt $185.0K · Total assets $45.0M · Shareholders' equity $38.3M
- Revenue
- $0
- Operating income
- −$10.1M
- Net income
- −$10.1M
No dividends on record.
| Institutions91 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 23.31% | 12.57M shares | |
| Insiders8 holders · as of Aug 12, 2026 | 15.16% | 8.18M shares | |
| Strategic holders1 holder · as of Jul 30, 2025 | 15.55% | 8.38M shares | |
| Otherremainder | ≈ 45.98% | 24.80M shares |
53.93M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Trill ABInstitution | 16.37% | 8.83M | 13Gfiled Feb 6, 2026 ↗ |
TomEnterprise AB1Strategicdirector | 15.55% | 8.38M | 13Gfiled Jul 30, 2025 ↗ |
Richard Ii JacintoInsider10 percent owner | 9.20% | 4.96M | 13Gfiled Nov 7, 2025 ↗ |
Cooperman Leon GInstitution | 6.40% | 3.45M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.18% | 2.25M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- TomEnterprise AB's transaction reports restate only vehicles that traded; the 2025 ownership statement (8.38M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 17, 2025 | Jan Stahlberg | 10 percent owner | +187,393 | $6.52 |
| Nov 18, 2025 | Jan Stahlberg | 10 percent owner | +182,882 | $6.75 |
| Nov 19, 2025 | Jan Stahlberg | 10 percent owner | +240,352 | $7.21 |
| Nov 20, 2025 | Jan Stahlberg | 10 percent owner | +128,426 | $7.41 |
| Nov 21, 2025 | Jan Stahlberg | 10 percent owner | +208,872 | $7.41 |
- Bristol-Myers Squibb
Phase 3 factor XIa inhibitor after ischemic stroke
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics | $6.76 | +4.81% | $363.7M | — | — | — | — |
| Bristol-Myers Squibb | $67.64 | −0.02% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Median | 14.9 | 10.6 | 2.8 | +5.7% |